NZ794954A - Nucleic acids and methods of treatment for cystic fibrosis - Google Patents
Nucleic acids and methods of treatment for cystic fibrosisInfo
- Publication number
- NZ794954A NZ794954A NZ794954A NZ79495421A NZ794954A NZ 794954 A NZ794954 A NZ 794954A NZ 794954 A NZ794954 A NZ 794954A NZ 79495421 A NZ79495421 A NZ 79495421A NZ 794954 A NZ794954 A NZ 794954A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cystic fibrosis
- treatment
- methods
- nucleic acids
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019170P | 2020-05-01 | 2020-05-01 | |
| US202063082997P | 2020-09-24 | 2020-09-24 | |
| PCT/US2021/030257 WO2021222801A2 (en) | 2020-05-01 | 2021-04-30 | Nucleic acids and methods of treatment for cystic fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ794954A true NZ794954A (en) | 2026-03-27 |
Family
ID=78374030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ794954A NZ794954A (en) | 2020-05-01 | 2021-04-30 | Nucleic acids and methods of treatment for cystic fibrosis |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12070509B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4143217A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023524071A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021263590A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3176844A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ794954A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021222801A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11801227B2 (en) | 2016-05-18 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| DK3864163T3 (da) | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| WO2021222801A2 (en) * | 2020-05-01 | 2021-11-04 | Arcturus Therapeutics, Inc. | Nucleic acids and methods of treatment for cystic fibrosis |
| CN116368226A (zh) | 2020-09-04 | 2023-06-30 | 维乎医疗有限公司 | 用于加帽rna的组合物和方法 |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| MX2023011227A (es) | 2021-03-22 | 2023-12-06 | Recode Therapeutics Inc | Composiciones y metodos para administracion dirigida a celulas. |
| MX2023011243A (es) | 2021-03-23 | 2023-12-14 | Recode Therapeutics Inc | Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos. |
| EP4334330A1 (en) | 2021-05-07 | 2024-03-13 | Helix Nanotechnologies, Inc. | Modified ribonucleic acids and uses thereof |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| US20250144237A1 (en) * | 2023-11-07 | 2025-05-08 | Cila Therapeutics Inc. | Agents, compositions and methods for enhanced delivery of nucleic acids to the cells within the respiratory system |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| US12364773B2 (en) | 2023-12-01 | 2025-07-22 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2026072721A1 (en) * | 2024-09-25 | 2026-04-02 | Carbon Biosciences, Inc. | Parvovirus compositions and methods for gene therapy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0079963B1 (en) | 1981-06-04 | 1986-08-27 | Delaware Chemicals Corporation | Pressurized container with dispensing pump |
| US4778810A (en) | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
| AU649074B2 (en) | 1990-10-12 | 1994-05-12 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| KR20040051450A (ko) * | 2002-12-12 | 2004-06-18 | 주식회사 인비보사이언스 | 알엔에이의 생체내 안정성을 증가시키는 벡터 |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EP2391343B1 (en) | 2009-01-29 | 2017-03-01 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
| CA3042927C (en) | 2009-05-05 | 2022-05-17 | Arbutus Biopharma Corporation | Lipid compositions for the delivery of therapeutic agents |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| CN104411338A (zh) * | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| KR102311614B1 (ko) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| CN110003066B (zh) * | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| WO2016070166A2 (en) | 2014-11-02 | 2016-05-06 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
| DK4276189T3 (da) | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| WO2018119163A1 (en) * | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
| MX2019010155A (es) * | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| EP3589290A4 (en) | 2017-02-28 | 2020-12-30 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| US11015204B2 (en) * | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
| WO2021222801A2 (en) * | 2020-05-01 | 2021-11-04 | Arcturus Therapeutics, Inc. | Nucleic acids and methods of treatment for cystic fibrosis |
| US20230159449A1 (en) * | 2021-11-03 | 2023-05-25 | Arcturus Therapeutics, Inc. | Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis |
-
2021
- 2021-04-30 WO PCT/US2021/030257 patent/WO2021222801A2/en not_active Ceased
- 2021-04-30 AU AU2021263590A patent/AU2021263590A1/en active Pending
- 2021-04-30 EP EP21795851.1A patent/EP4143217A4/en active Pending
- 2021-04-30 NZ NZ794954A patent/NZ794954A/en unknown
- 2021-04-30 CA CA3176844A patent/CA3176844A1/en active Pending
- 2021-04-30 US US17/246,558 patent/US12070509B2/en active Active
- 2021-04-30 JP JP2022566343A patent/JP2023524071A/ja active Pending
-
2024
- 2024-06-04 US US18/732,954 patent/US20250049950A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12070509B2 (en) | 2024-08-27 |
| WO2021222801A3 (en) | 2021-12-09 |
| US20250049950A1 (en) | 2025-02-13 |
| EP4143217A4 (en) | 2024-10-02 |
| EP4143217A2 (en) | 2023-03-08 |
| WO2021222801A2 (en) | 2021-11-04 |
| JP2023524071A (ja) | 2023-06-08 |
| CA3176844A1 (en) | 2021-11-04 |
| AU2021263590A1 (en) | 2023-01-19 |
| US20220023442A1 (en) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021222801A3 (en) | Nucleic acids and methods of treatment for cystic fibrosis | |
| JP7235702B2 (ja) | 核酸生成及び送達のための方法及び製品 | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| Merckx et al. | Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy | |
| MX2022012630A (es) | Composicion de nanoparticulas lipidicas. | |
| PH12023500013A1 (en) | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof | |
| Zuris et al. | Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo | |
| Kormann et al. | Expression of therapeutic proteins after delivery of chemically modified mRNA in mice | |
| MX2022009018A (es) | Nanoparticulas lipidas. | |
| MX2021014911A (es) | Lípidos sintéticos para administración de arnm. | |
| PH12022552327A1 (en) | Compositions and methods for targeted rna delivery | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| ZA202300131B (en) | Lipid nanoparticles | |
| MX2024015149A (es) | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos | |
| Zhang et al. | Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination | |
| EP4406585A3 (en) | Nucleic acid products and methods of administration thereof | |
| AU2018268859A1 (en) | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR | |
| MX2023005203A (es) | Nanoparticulas lipidicas para administrar vacunas de arnm. | |
| EP3818991A3 (en) | Compositions and methods for treating diseases | |
| PL1885382T3 (pl) | Sposoby stosowania komórek pochodzących z tkanki tłuszczowej w leczeniu stanów układu sercowo-naczyniowego | |
| MX2025010536A (es) | Nuevas formulaciones de nanoparticulas lipidicas para la administracion de acidos nucleicos | |
| MX2024013583A (es) | Formulaciones de nanopartículas lipídicas para suministro al sistema nervioso central | |
| Pan et al. | Biomimetic bacteria-derived nanoclusters enhance ferroptosis cancer immunotherapy through synergistic CRISPR-photothermo modulation | |
| MX2025002413A (es) | Nuevos lipidos ionizables y nanoparticulas de lipidos y metodos de uso de los mismos | |
| Wang et al. | Morphology–and adhesion–dual biomimetic nanovaccine boosts antigen cross-presentation through subcellular transport regulation |